Rehabilitation for people recovering from tuberculosis lung disease
Official title: Rehabilitation of People With Post-tuberculosis Lung Disease
Run by Centro Universitário Augusto Motta · NCT06127641 · Data updated 2026-11-12
This study is testing if a 12-week rehabilitation program can help people recovering from tuberculosis lung disease feel better and improve their daily activities compared to standard care.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Centro Universitário Augusto Motta Academic / other |
| Locations | 2 sites (Rio de Janeiro and 1 other locations) |
| Status | Recruiting |
| Started | October 28, 2023 |
| Main results expected | December 31, 2024 |
| Study ends | December 31, 2027 |
| Registry record updated | November 13, 2023 |
| Trial ID | NCT06127641 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients with clinically stable post-tuberculosis lung disease who can participate in at least 80% of the training sessions.
✕Probably not a fit
Patients with significant comorbidities unrelated to PD-PTB or those unable to perform the required tests may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the impact of pulmonary rehabilitation on the functionality and health-related quality of life of individuals suffering from post-tuberculosis lung disease (PD-PTB). It involves a randomized controlled trial where participants will be divided into two groups: one receiving standard care and the other undergoing a 12-week pulmonary rehabilitation program. The study will assess functional capacity using the Glittre-ADL test, along with evaluations of lung function, muscle function, fatigue, and overall quality of life. Additionally, an artificial intelligence-based scoring system for PD-PTB severity will be developed based on the collected data.
Why it matters
Potential benefit: If successful, this study could significantly improve the quality of life and functional capabilities of patients recovering from tuberculosis lung disease.
How similar studies have gone: Other studies have shown promising results with pulmonary rehabilitation in similar patient populations, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with post-tuberculosis lung disease, clinically stable and able to perform \>80% of training sessions. Exclusion Criteria: * Presence of comorbidities not related to PD-PTB. * Patients with inability to perform TGlittre. * Patients who have cognitive changes that impair their inclusion in the study. * Treatment abandonment during the application of the PR protocol. * Uncontrolled hypertension or use of psychotropic medications. * Any significant limitations due to osteoarthropathy. * Having had any orthopedic surgery in the previous year.
Where it's running
-
Agnaldo José Lopes
Rio de Janeiro, Brazil Recruiting -
Centro Universitario Augusto Motta
Rio de Janeiro, Brazil Recruiting
Study contacts
- Study coordinator: Agnaldo José Lopes, DsC
- Email: agnaldolopes.uerj@gmail.com
- Phone: +55 21998536162
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Channa striata and Curcuma Domestica Supplements in Active Pulmonary TB
This study tests whether adding Channa striata extract and Curcuma domestica to standard TB care helps improve nutrition, inflammation, and quality of life in adults with active pulmonary tuberculosis.
-
PAN-USR: a universal ultra-short treatment for pulmonary tuberculosis
This trial tests whether a new 2–3 month drug regimen works and is safe for adults with active pulmonary tuberculosis, including drug-resistant cases.
-
Shorter treatment for low-risk active tuberculosis
This study is testing if a shorter 4-month treatment for low-risk pulmonary tuberculosis works just as well as the usual 6-month treatment for newly diagnosed patients.
-
Using breath analysis to identify multiple lung diseases
This study is testing if analyzing breath samples can help identify different lung diseases like lung cancer and COPD in a large group of 10,000 people.
-
Using Atorvastatin to treat Pulmonary Tuberculosis
This study is testing if adding Atorvastatin, a cholesterol-lowering drug, can help people with pulmonary tuberculosis get better when they start treatment.
-
New treatments for pulmonary tuberculosis
This study is testing new combinations of two drugs with existing TB treatments to see if they can help people with pulmonary tuberculosis get better in a shorter time than the usual 24 weeks.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.